TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Implant: The implant is structured to release the therapeutic component for a first period of time, to release no therapeutic component for a second period of time after the first period of time, and to release the therapeutic component for a third period of time after the second period of time, the first, second and third periods of time being after intraocular implantation of the implant. The implant has a layered structure and comprises several particles which are differently structured to facilitate the discontinuous or intermittent release of the therapeutic component after intraocular implantation of the implant and to release the therapeutic component during different periods of time after intraocular implantation of the implant. The intraocular implant system further comprises a second implant sized and adapted for intraocular placement and comprising an auxiliary agent associated with a biodegradable polymer, the first and second implants is structured to release at least one of the therapeutic component and the auxiliary agent discontinuously or intermittently after intraocular placement. The first and second implants are included in a single intraocular implant sized and adapted for intraocular placement or included in different implant portions sized and adapted for intraocular placement at the same time. The first and second implants is structured to release at least one of the therapeutic component and the auxiliary agent so that only one of the therapeutic component and the auxiliary agent (preferably only the auxiliary agent) is being released during at least one period of time after intraocular placement. Each different implant portion is structured to release, after intraocular placement, at least one of the therapeutic component and the auxiliary agent according to at least one parameter selected from a) a different time, and/or b) a different rate, from at least one other implant portion. The therapeutic component and the auxiliary agent are associated with the same biodegradable polymer. The therapeutic component and the auxiliary agent are present in different portions of the single intraocular implant. The first and second implants has a layered structure to facilitate the discontinuous or intermittent release of at least one of the therapeutic component and the auxiliary agent after intraocular placement. The particles (elements) are differently structured. The first and second implants comprise several particles including particles with release the therapeutic component and the auxiliary agent during different periods of time after intraocular placement. The pulsatile release treats the ocular condition by inhibiting an inflammatory cell function or by inhibiting genesis or proliferation of an inflammatory cell. Each of the first, second and third periods of time is at least 1 (preferably 2) weeks. Preferred Components: The auxiliary agent comprises a different therapeutic component. The auxiliary agent is selected from anti-glaucoma drugs (including neuroprotectants), antibiotics, vitamins, nucleotides, chaperone proteins and carrier proteins. The therapeutic component comprises a steroid antiangiogenics, neuroprotectants, antibiotics antiviral agents and nonsteroidal antiinflammatory drug (preferably steroid selected from cortisone, prednisolone, flurometholone, dexamethasone, medrysone, loteprednol, fluazacort, hydrocortisone, prednisolone, betamethasone, prednisone, methylprednisolone, hamcinolone hexacatonide, paramethasone acetate, triamcinolone acetonide, diflorasone and/or fluocinonide) and the auxiliary agent comprises an anti-glaucoma drug. The biodegradable polymer comprises a poly (lactide-co-glycolide) (PLGA) copolymer. ACTIVITY - Ophthalmological; Antiinflammatory; Vasotropic; Cytostatic; Antimicrobial; Tranquilizer; Vulnerary; Antiulcer; Fungicide; Virucide; Antidiabetic. An 82 year old female diagnosed with macular degeneration in her right eye was treated by intravitreal placement of a biodegradable implant containing of fluocinolone acetonide (600 micrograms) and poly (lactide-co-glycolide) (PLGA) (500 micrograms). The implant was placed near the fovea without interfering with the patient's vision. Further ophthalmic diagnosis indicated that macular degeneration was suspended, and the patient does not perceive further vision loss associated with macular degeneration. Throughout the treatment, intraocular pressure remained within acceptable limits.    MECHANISM OF ACTION - None given.    ADMINISTRATION - Administration is ophthalmically (by intravitreal delivery, or subconjunctival delivery). No dosage details given.